The Pharmacology of Obesity

Editors

Barbara S. Slusher, PhD, MAS (Volume Editor) and Diane Peters, PhD (Volume Editor)

ISBN: 9780443474606

Published: November 2026

Format: Hardcover

Language: English

Publisher: Academic Press (Elsevier)

Description

The Pharmacology of Obesity is Volume 107 of the Advances in Pharmacology series, bringing together an international group of researchers and clinicians to map the fast-moving pharmacological landscape of obesity care. Anchored by the clinical transformation driven by GLP-1 receptor agonists, the volume moves from diagnosis and the current therapeutic landscape through emerging drug targets, nutrition and behavioral strategies, digital health tools, metabolic aging, endoscopic therapies, and bariatric surgery candidacy — giving clinicians, researchers, and libraries a single, current reference for how obesity pharmacology is being practiced and studied today.

Key Features

Equips clinical pharmacologists and endocrinologists to evaluate and sequence GLP-1 receptor agonists and next-generation anti-obesity agents against emerging alternatives.

Gives program directors and formulary committees a practical framework for weighing pharmacotherapy against endoscopic and bariatric surgical pathways for individual patients.

Supports researchers designing new obesity drug-discovery programs with a current map of validated and investigational molecular targets.

Coverage

The current therapeutic landscape and diagnosis of obesity; GLP-1 receptor agonists and their mechanisms and clinical use; future and investigational anti-obesity drug targets; nutrition, physical activity, and behavioral strategies in pharmacological weight management; body-composition metrics and digital health tools; metabolic aging and its pharmacological implications; endoscopic therapies for obesity; and determining candidacy for bariatric surgery.

About the Authors

Barbara S. Slusher, PhD, MAS, directs the Johns Hopkins Drug Discovery Program at the Johns Hopkins University School of Medicine, where her research translates neuropharmacology and metabolic-disease targets into new therapeutics. Diane Peters, PhD, co-edits this volume. Together with contributing authors drawn from endocrinology, bariatric medicine, and pharmacology programs, they bring a multidisciplinary clinical and research perspective to the series.

Table of Contents

1. The Current Therapeutic Landscape in Obesity Medicine
2. Diagnosis and Clinical Assessment of Obesity
3. GLP-1 Receptor Agonists: Mechanisms and Clinical Use
4. Future and Investigational Anti-Obesity Drug Targets
5. Nutrition and Physical Activity in Pharmacological Weight Management
6. Behavioral Strategies to Support Pharmacotherapy
7. Body-Composition Metrics in Obesity Care
8. Digital Health Tools for Weight Management
9. Metabolic Aging and Obesity Pharmacology
10. Endoscopic Therapies for Obesity
11. Determining Candidacy for Bariatric Surgery
12. Integrating Pharmacological and Procedural Approaches
13. Future Directions in Obesity Pharmacology

Why buy this book?

It is a single-volume synthesis of a fast-moving field, built on the peer-reviewed Advances in Pharmacology series. It covers the GLP-1 era in direct, clinically usable terms, and gives academic and hospital libraries a current reference that bridges pharmacology, endocrinology, and bariatric medicine. It includes a downloadable e-version with every print purchase.

Keywords

obesity pharmacology, GLP-1 receptor agonists, anti-obesity drugs, bariatric medicine, metabolic aging, weight management, endocrinology, clinical pharmacology, digital health for obesity care, bariatric surgery candidacy

Target Audience

Clinical pharmacologists, endocrinologists, obesity medicine specialists, bariatric surgeons, academic medical libraries, pharmacology researchers

Genre

Pharmacology, Endocrinology

Q&A

What does The Pharmacology of Obesity cover?
It is Volume 107 of the Advances in Pharmacology series, covering the current and emerging pharmacological treatment of obesity, from GLP-1 receptor agonists to future drug targets, behavioral and digital health strategies, and bariatric surgery candidacy.

Who are the editors of this volume?
The volume is edited by Barbara S. Slusher, PhD, MAS, Director of the Johns Hopkins Drug Discovery Program, together with Diane Peters, PhD, with contributions from an international group of pharmacology and obesity-medicine specialists.

Does this book cover GLP-1 receptor agonists?
Yes. A dedicated chapter addresses GLP-1 receptor agonists, their mechanisms and clinical use, and how they compare with emerging anti-obesity drug targets.

Is this book suitable for academic and hospital libraries?
Yes. As part of the peer-reviewed Advances in Pharmacology series from Academic Press/Elsevier, it is designed as a reference for academic medical libraries, pharmacology departments, and hospital collections.

Where can I buy The Pharmacology of Obesity?
You can order The Pharmacology of Obesity directly from CLNZ Books. Price includes worldwide shipping.

📘 Learn more about shipping, delivery times, and returns, see our FAQ here

📦 New to ordering with us? See our How to Order guide for payment, shipping, and institutional order options.